OPTI!!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
So wouldn't those holders have a vested interest in the PPS going above $3.68?
I figured...thought I was losing my mind for s sec
Uh...what??
Yes...what he said
Wow...what's with all the buying?
If you don't like the stock or the company....why be in here?
Well said
If you're unhappy about PPS, and aren't spreading the news and slapping the ask....sit quietly and wait!
Why is that sticky there???
Like most, buyout imminent.
Sweet....it begins ....
It's pretty market positioning. Relax
Due for a rip
Actually seems like lower volume is helping...
Too much volume is too many people back and forth consolidation.
Doesn't let it move.
Looking strong today.
Eyes on .3
Up up and away...good job bulls
All the negativity just illustrates the amount of shorters in the room, trying to make their money.
Pick a different stock.. this needs to run to $1+
This sideways action helps nobody.
She wants to rip.
Lead, follow, or get out of the way.
No-no-no-DTCH
But social media usually followed up with news AH.
Better buy in now. TX news may be imminent.
Did it get filled??
Tweet is missing a word. (Be)
only 100K to .068 BUY!!!
I'm fully loaded.
Exactly...hit that .22 - 23 wall...bust through..smooth sailing to .40.
Need to all buy at same time on the ask. Blitz it at noon. Lol
Why posting this? (Tricatdia)
Nice little dip earlier...picked up some more on the ask.
Nice.
No wonder they're out in full force.
https://cnafinance.com/delcath-systems-dcth-stock-traders-likely-to-take-advantage-of-short-sale-restriction/15772
RS is voted down. Off the table.
They're out in full force today.
Must be something brewing
Nobody painted it back up.
What happened EOD??
I'd have to agree. Financials and potential are seriously iffy.
Not worth risk.
REPOST OF STOCKWHALE'S EXCELLENT POST FROM YESTERDAY:
$DCTH Highlights for the first quarter of 2017 and the recent weeks include:
First quarter 2017 revenue of $0.74 million, an increase of 100% compared with revenue of $0.37 million in prior year quarter.
CHEMOSAT treatment milestone set by SPIRE Southampton Hospital in the U.K. with more than 100 CHEMOSAT treatments performed, including eight treatments on a single patient.
Announced a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA) for the design of a pivotal trial of Melphalan/HDS to treat patients with intrahepatic cholangiocarcinoma (ICC).
The American Journal of Clinical Oncology published a single-center retrospective review finding that the Company’s investigational percutaneous hepatic perfusion (PHP) with Melphalan/HDS offered promising results with a doubling of overall survival (OS), significantly longer progression-free survival (PFS) and hepatic progression-free survival (hPFS) compared with other targeted therapies.
Favorable data from two institutions were presented at the Regional Cancer Therapies Symposium and showed strong tumor response and overall survival with the Company’s investigational PHP therapy in patients with ocular melanoma that metastasized to the liver.
“During the first three months of 2017 we continued to advance our clinical development programs in ocular melanoma liver metastases and intrahepatic cholangiocarcinoma, while making steady progress with commercialization of CHEMOSAT in Europe,” said Jennifer K. Simpson, Ph.D., MSN, CRNP President and CEO of Delcath."
“As we announced recently, we have concluded a new SPA agreement with the FDA for the initiation of a pivotal trial for the use of Melphalan/HDS in patients with ICC. This new trial will enroll approximately 295 ICC patients at about 40 clinical sites in the U.S. and Europe, with the primary endpoint of overall survival and with secondary and exploratory endpoints that include safety, progression-free survival, objective response rate and quality-of-life measures. The trial is designed to be cost-effective and conducted in a financially prudent manner, with modest investment in this fiscal year. In conjunction with the FOCUS Trial in ocular melanoma liver metastases, our clinical development programs now include two paths toward potential U.S. market approvals.
“In Europe, we continue to make steady progress with the commercialization of CHEMOSAT. Our first quarter revenue of more than $0.7 million was double the prior year period’s sales, driven primarily by national reimbursement in Germany under the ZE system. With coverage under the ZE system now in place, we expect product sales growth from this market for the remainder of 2017."
"Elsewhere in Europe, we continue to focus on building the clinical and pharmacoeconomic data to support reimbursement applications in other key markets. We expect that positive negotiations for coverage in Germany will support our efforts for payment levels in other markets such as the U.K. and the Netherlands. Securing reimbursement coverage in additional European markets remains critical to future revenue growth for CHEMOSAT,” concluded Dr. Simpson.
As of March 31, 2017, Delcath had cash and cash equivalents of $6.4 million, compared with $4.4 million as of December 31, 2016. During the first quarter of 2017, the Company used $3.8 million of cash to fund operating activities. Delcath believes it has sufficient capital and access to committed capital to fund its operating activities through the end of 2017.
Also check out this article, pretty good read:
https://insiderfinancial.com/heres-what-comes-next-from-delcath-systems-inc-nasdaqdcth
Post the DD again. People have short memories
8s and tickled 9s by EOD....looks like it
Wow...such manipulation.
Look at these tiny size bids.
Did this yesterday around .18 and ny idiot ass sold. ..then it shot to .22 in 20 mins.
Who the heck sold???
Etrade acquired them...hopefully will get new pricing when transitioned
Yeah. Sucks. They charge .0005 per share for penny stocks
And Robinhood doesn't do penny's at all
Optionshouse by etrade.
Can't avg down if I'm charged 5 bucks for every 10000 shares.